As Abecma sales take off, Bristol Myers and 2seventy scrap a follow-up CAR-T

Bristol Myers Squibb and bluebird bio spinout 2seventy are axing a CAR-T program in the wake of rising Abecma sales.

The companies will cease all development for the program in question, bb21217, “based on the strength of the Abecma clinical data and high commercial interest,” 2seventy said in a press release Tuesday. It’s the second anti-BCMA CAR-T that Bristol Myers halted in the last year after ejecting a Juno-developed program last February.